A Cost-utility Analysis of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis: a Scottish Perspective

Overview

Journal Eur J Health Econ

Specialty Health Services

Date 2015 Mar 22

PMID 25795391

Citations 5

Authors

Keith Tolley

Danny Kemmett

Signe Thybo

Ruth Nasr

Helen Smethurst

Affiliations

Soon will be listed here.

Abstract

Background: Actinic keratosis (AK) is a UV-induced, pre-malignant skin condition that is common in adults over 60 years of age with fair skin in Scotland. The most commonly prescribed first-line treatment for AK in Scotland is currently diclofenac gel (3 %). Ingenol mebutate gel is a recently developed topical therapy available in two strengths for the treatment of AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days).

Objective: To compare the cost-effectiveness of two strengths of ingenol mebutate gel developed to treat AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days) with other first-line AK therapies including diclofenac gel, 5-FU, 5-FU/salicylic acid, and cryotherapy for the first-line treatment of AK in adult patients, from the perspective of the National Health Service (NHS) in Scotland.

Methods: A cost-utility analysis was conducted using a decision-tree approach to calculate the costs and benefits of different treatment strategies for AK on the face and scalp or trunk and limbs over a 12-month time horizon. Data on the relative efficacy of treatments were obtained from a systematic literature review and meta-analysis. Utility scores and resource-use data were obtained from published sources.

Results: Over 12 months, ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were cost-effective compared with the most commonly used topical therapy in Scotland, diclofenac (3 %) gel, at a willingness-to-pay threshold of £20,000 per QALY, with a minimal additional cost of £43 and £105, respectively per QALY gained.

Conclusions: Ingenol mebutate gel is a cost-effective therapy for the first-line treatment of AK from a Scottish NHS perspective.

Citing Articles

Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland.

Dymond A, Green W, Edwards M, Pont M, Gupta G Pharmacoecon Open. 2023; 7(3):443-454.

PMID: 37012513 PMC: 10170011. DOI: 10.1007/s41669-023-00410-5.

Mediators of Inflammation in Topical Therapy of Skin Cancers.

Voiculescu V, Lisievici C, Lupu M, Vajaitu C, Draghici C, Popa A Mediators Inflamm. 2019; 2019:8369690.

PMID: 30766448 PMC: 6350587. DOI: 10.1155/2019/8369690.

Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression.

Philipp-Dormston W, Muller K, Novak B, Stromer K, Termeer C, Hammann U J Eur Acad Dermatol Venereol. 2017; 32(7):1138-1146.

PMID: 29150868 PMC: 6032898. DOI: 10.1111/jdv.14703.

Pharmacoeconomic evaluations in the treatment of actinic keratoses.

Tolley K, Argenziano G, Calzavara-Pinton P, Larsson T, Ryttig L Int J Immunopathol Pharmacol. 2017; 30(2):178-181.

PMID: 28580871 PMC: 5806796. DOI: 10.1177/0394632017697719.

Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.

Vale S, Hill D, Feldman S Pharmacoeconomics. 2016; 35(2):177-190.

PMID: 27785771 DOI: 10.1007/s40273-016-0462-4.

References

Morris S, Cox B, Bosanquet N . Cost of skin cancer in England. Eur J Health Econ. 2008; 10(3):267-73. DOI: 10.1007/s10198-008-0127-0. View

Littenberg B, Partilo S, Licata A, Kattan M . Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med Decis Making. 2003; 23(6):480-8. DOI: 10.1177/0272989X03259817. View

Einspahr J, Stratton S, Timothy Bowden G, Alberts D . Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002; 41(3):269-85. DOI: 10.1016/s1040-8428(01)00185-8. View

Gebauer K, Brown P, Varigos G . Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003; 44(1):40-3. DOI: 10.1046/j.1440-0960.2002.00635.x. View

Weinstock M, Lee K, Chren M, Marcolivio K . Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial. J Am Acad Dermatol. 2009; 61(2):207-15. PMC: 3614359. DOI: 10.1016/j.jaad.2009.02.022. View

Marks R, Foley P, Goodman G, Hage B, Selwood T . Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986; 115(6):649-55. DOI: 10.1111/j.1365-2133.1986.tb06644.x. View

Szeimies R, Karrer S, Sauerwald A, Landthaler M . Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology. 1996; 192(3):246-51. DOI: 10.1159/000246376. View

Thomas K, Keogh-Brown M, Chalmers J, Fordham R, Holland R, Armstrong S . Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. Health Technol Assess. 2006; 10(25):iii, ix-87. DOI: 10.3310/hta10250. View

Chen S, Bayoumi A, Soon S, Aftergut K, Cruz P, Sexton S . A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc. 2004; 9(2):160-8. DOI: 10.1046/j.1087-0024.2003.09112.x. View

10.

Briggs A . Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000; 17(5):479-500. DOI: 10.2165/00019053-200017050-00006. View

11.

Harvey I, Frankel S, Marks R, Shalom D . Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer. 1996; 74(8):1302-7. PMC: 2075913. DOI: 10.1038/bjc.1996.534. View

12.

Briggs A, OBrien B, Blackhouse G . Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002; 23:377-401. DOI: 10.1146/annurev.publhealth.23.100901.140534. View

13.

Lebwohl M, Swanson N, Anderson L, Melgaard A, Xu Z, Berman B . Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012; 366(11):1010-9. DOI: 10.1056/NEJMoa1111170. View

14.

Wilson E . Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics. 2010; 28(11):1055-64. DOI: 10.2165/11538670-000000000-00000. View

15.

Jeffes E, McCullough J, Weinstein G, Fergin P, Nelson J, Shull T . Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol. 1997; 133(6):727-32. View

16.

Feldman S, Fleischer Jr A . Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011; 87(4):201-7. View

17.

Muston D, Downs A, Rives V . An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat. 2009; 20(5):266-75. DOI: 10.1080/09546630902887211. View

18.

Stockfleth E, Kerl H, Zwingers T, Willers C . Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011; 165(5):1101-8. DOI: 10.1111/j.1365-2133.2011.10387.x. View

19.

Jorizzo J, Dinehart S, Matheson R, Moore J, Ling M, Fox T . Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007; 57(2):265-8. DOI: 10.1016/j.jaad.2007.01.047. View

20.

Taub A, Garretson C . A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J Drugs Dermatol. 2011; 10(9):1049-56. View